

Eleanor Barnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2806679/publications.pdf>

Version: 2024-02-01

256
papers

29,134
citations

14614

66
h-index

6979

154
g-index

301
all docs

301
docs citations

301
times ranked

38384
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the key intrahepatic gene networks in HCV infection driven by sex. <i>Gut</i> , 2023, 72, 984-994.	6.1	3
2	Implementation of a controlled human infection model for evaluation of HCV vaccine candidates. <i>Hepatology</i> , 2023, 77, 1757-1772.	3.6	5
3	SARS-CoV-2 in Pediatric Liver Transplant Recipients. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, .	0.9	5
4	SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination. <i>Hepatology Communications</i> , 2022, 6, 889-897.	2.0	36
5	Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead. <i>Journal of Hepatology</i> , 2022, 76, 981-982.	1.8	5
6	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e21-e31.	3.4	131
7	Adenovirus vectors activate $\gamma\delta$ T cells in a type I interferon, TNF, and IL-18-dependent manner. <i>European Journal of Immunology</i> , 2022, 52, 835-837.	1.6	3
8	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
9	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. <i>Cell</i> , 2022, 185, 916-938.e58.	13.5	164
10	Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis.. <i>Clinical and Translational Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.3	2
11	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. Efficacy and Mechanism Evaluation, 2022, 9, 1-54.	0.9	2
12	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, , ASN.2021121587.	3.0	4
13	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
14	Infection of liver hepatocytes with SARS-CoV-2. <i>Nature Metabolism</i> , 2022, 4, 301-302.	5.1	16
15	A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice. <i>Hepatology</i> , 2022, 76, 1190-1202.	3.6	12
16	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
17	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
18	A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells. <i>Journal of Immunological Methods</i> , 2022, 504, 113263.	0.6	4

#	ARTICLE	IF	CITATIONS
19	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1213-1226.	2.0	9
20	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. <i>Gut</i> , 2022, 71, 1919.2-1922.	6.1	3
21	NK cells limit therapeutic vaccine-induced CD8 ⁺ T cell immunity in a PD-L1-dependent manner. <i>Science Translational Medicine</i> , 2022, 14, eabi4670.	5.8	19
22	Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers. <i>Clinical and Experimental Immunology</i> , 2022, 209, 90-98.	1.1	5
23	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
24	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	2.3	24
25	Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 20 years after allogeneic bone marrow transplant. <i>British Journal of Haematology</i> , 2022, 198, 668-679.	1.2	13
26	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
27	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. <i>Nature Microbiology</i> , 2022, 7, 1161-1179.	5.9	352
28	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. <i>Journal of Hepatology</i> , 2021, 74, 567-577.	1.8	377
29	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 168-176.	1.0	7
30	Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus. <i>Abdominal Radiology</i> , 2021, 46, 1947-1957.	1.0	11
31	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
32	Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 493-507.	1.0	42
33	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
34	COVID-19 and liver transplantation: the jury is still out – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 11.	3.7	1
35	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
36	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021, 371, 521-526.	6.0	88

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 156-158.	3.7	49
38	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 348-364.	8.2	272
39	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
40	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1951.	5.8	54
41	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
42	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	13.5	936
43	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	13.5	442
44	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9.	13.5	519
45	Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1110-1120.	1.0	12
46	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab267.	0.4	6
47	SARS-CoV-2 infection in patients with autoimmune hepatitis. <i>Journal of Hepatology</i> , 2021, 74, 1335-1343.	1.8	90
48	Therapeutic vaccination for treatment of chronic hepatitis B. <i>Clinical and Experimental Immunology</i> , 2021, 205, 106-118.	1.1	36
49	Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 610.	1.3	9
50	Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1256-1264.	1.0	16
51	The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization. <i>Gastroenterology</i> , 2021, 160, 2599-2601.e2.	0.6	11
52	Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 75, 226-228.	1.8	16
53	Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019. <i>Hepatology Communications</i> , 2021, 5, 1586-1604.	2.0	7
54	Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a. <i>Virus Evolution</i> , 2021, 7, veab065.	2.2	0

#	ARTICLE	IF	CITATIONS
55	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021, 8, e474-e485.	2.1	190
56	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
57	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
58	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	2.1	39
59	FXR antagonists as new agents for COVID-19. , 2021, , .		1
60	Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: International registry data. , 2021, , .		1
61	Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination. <i>Npj Vaccines</i> , 2021, 6, 117.	2.9	3
62	Cell-free DNA TAPS provides multimodal information for early cancer detection. <i>Science Advances</i> , 2021, 7, eabh0534.	4.7	41
63	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
64	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. <i>Nature Communications</i> , 2021, 12, 6105.	5.8	11
65	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , 2021, 3, 100384.	2.6	10
66	SARS-CoV-2 Infection in patients with autoimmune hepatitis. , 2021, , .		2
67	Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. <i>Hepatology</i> , 2020, 71, 794-807.	3.6	18
68	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020, 23, 180-190.	0.1	1
69	A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	39
70	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
71	Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. <i>Journal of Clinical Virology</i> , 2020, 129, 104548.	1.6	16
72	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet</i> , 2020, 396, 467-478.	6.3	2,080

#	ARTICLE	IF	CITATIONS
73	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet</i> , The, 2020, 396, 1979-1993.	6.3	1,196
74	Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. <i>Frontiers in Microbiology</i> , 2020, 11, 576572.	1.5	13
75	Impact of virus subtype and host <i>IFNL4</i> genotype on large-scale RNA structure formation in the genome of hepatitis C virus. <i>Rna</i> , 2020, 26, 1541-1556.	1.6	7
76	Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. <i>Liver International</i> , 2020, 40, 3071-3082.	1.9	37
77	Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. <i>Npj Vaccines</i> , 2020, 5, 94.	2.9	15
78	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020, 21, 1336-1345.	7.0	1,066
79	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1390-1400.	4.6	336
80	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1008-1016.	3.7	194
81	Genome-wide association study for alcohol-related cirrhosis identifies new risk loci in <i>MARC1</i> and <i>HNRNPUL1</i> . <i>Journal of Hepatology</i> , 2020, 73, S117-S118.	1.8	0
82	The Application of Single-Cell RNA Sequencing in Vaccinology. <i>Journal of Immunology Research</i> , 2020, 2020, 1-19.	0.9	30
83	A multi-disciplinary approach to IgG4 related disease aids in diagnosis and management. <i>Journal of Hepatology</i> , 2020, 73, S487-S488.	1.8	0
84	The predictive value of MRI-based markers of liver disease on clinical outcomes in patients with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S773-S774.	1.8	0
85	Optimising delivery of therapeutic hepatitis B vaccines to induce resident memory T cells in the liver. <i>Journal of Hepatology</i> , 2020, 73, S886.	1.8	2
86	Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir. <i>Journal of Hepatology</i> , 2020, 73, S336.	1.8	3
87	Correspondence on "The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease"™. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-218894.	0.5	2
88	Determining risk factors for mortality in liver transplant patients with COVID-19. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 643-644.	3.7	90
89	The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. <i>Trials</i> , 2020, 21, 413.	0.7	5
90	Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. <i>Journal of Hepatology</i> , 2020, 73, 794-799.	1.8	27

#	ARTICLE	IF	CITATIONS
91	Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. <i>Vaccine</i> , 2020, 38, 5036-5048.	1.7	13
92	MHC class II invariant chain“adjuvanted viral vectored vaccines enhances T cell responses in humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	20
93	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , 2020, 159, 1276-1289.e7.	0.6	53
94	Characterizing Hepatitis C Virus“Specific CD4+ T Cells Following Viral“Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure. <i>Hepatology</i> , 2020, 72, 1541-1555.	3.6	15
95	Expansion of a Novel Subset of PD1+CXCR5-CD4+ T Peripheral Helper Cells in IgG4-Related Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00111.	1.3	8
96	The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. <i>Vaccines</i> , 2020, 8, 184.	2.1	21
97	Accurate non“invasive diagnosis and staging of non“alcoholic fatty liver disease using the urinary steroid metabolome. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1188-1197.	1.9	13
98	Divergent chemokine receptor expression and the consequence for human IgG4 B“cell responses. <i>European Journal of Immunology</i> , 2020, 50, 1113-1125.	1.6	18
99	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. <i>Wellcome Open Research</i> , 2020, 5, 240.	0.9	2
100	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results“from an international registry. <i>Journal of Hepatology</i> , 2020, 73, 705-708.	1.8	213
101	National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research. <i>BMJ Health and Care Informatics</i> , 2020, 27, e100145.	1.4	14
102	Antibody testing for COVID-19: A report from the“National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020, 5, 139.	0.9	179
103	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. <i>Wellcome Open Research</i> , 2020, 5, 113.	0.9	9
104	Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms. <i>Wellcome Open Research</i> , 2020, 5, 151.	0.9	10
105	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	0.9	81
106	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	0.9	122
107	Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses. <i>ELife</i> , 2020, 9, .	2.8	55
108	Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease. <i>Clinical Medicine</i> , 2020, 20, e32-e39.	0.8	7

#	ARTICLE	IF	CITATIONS
109	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. Wellcome Open Research, 2020, 5, 113.	0.9	5
110	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. Wellcome Open Research, 2020, 5, 240.	0.9	3
111	Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study. PLoS ONE, 2019, 14, e0221066.	1.1	27
112	Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology, 2019, 157, 692-704.e9.	0.6	27
113	Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. Journal of Interferon and Cytokine Research, 2019, 39, 642-649.	0.5	6
114	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. Journal of Infection, 2019, 79, 503-512.	1.7	23
115	IgG4-related disease. Medicine, 2019, 47, 804-807.	0.2	0
116	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Medicine, 2019, 17, 175.	2.3	17
117	FRI-162-Prime-boost vaccination strategies using chimpanzee-Adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice. Journal of Hepatology, 2019, 70, e459-e460.	1.8	2
118	Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection. MBio, 2019, 10, .	1.8	24
119	Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV). Scientific Reports, 2019, 9, 7081.	1.6	75
120	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value in Health, 2019, 22, 693-703.	0.1	13
121	Interpreting Viral Deep Sequencing Data with GLUE. Viruses, 2019, 11, 323.	1.5	29
122	PTU-100...The role of a multi-regional specialist multi-disciplinary meeting in diagnosis and management of igg4-related disease. , 2019, , .		0
123	Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. Clinical and Translational Gastroenterology, 2019, 10, e00020.	1.3	29
124	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology, 2019, 156, 418-430.	0.6	162
125	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	3.7	370
126	Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1878-1886.	1.4	30

#	ARTICLE	IF	CITATIONS
127	Clinical Manifestations and Long-term Outcomes of IgG4-Related Kidney and Retroperitoneal Involvement in United Kingdom IgG4-Related Disease Cohort. <i>Kidney International Reports</i> , 2019, 4, 48-58.	0.4	29
128	Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 32-44.	3.7	22
129	Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. <i>Hepatology</i> , 2019, 69, 1861-1872.	3.6	68
130	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <i>ELife</i> , 2019, 8, .	2.8	28
131	Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8+ T Cells by Persistent Viruses and Vaccines. <i>Cell Reports</i> , 2018, 23, 768-782.	2.9	79
132	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 562-574.	2.7	71
133	Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. <i>Hepatology</i> , 2018, 68, 859-871.	3.6	18
134	Hepatic iron is the major determinant of serum ferritin in NAFLD patients. <i>Liver International</i> , 2018, 38, 164-173.	1.9	65
135	Interferon- γ induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study. <i>Psychological Medicine</i> , 2018, 48, 998-1007.	2.7	18
136	The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. <i>Vaccine</i> , 2018, 36, 313-321.	1.7	32
137	OTU-020...Altered FC and FAB glycosylation status in patients with IGG4-related sclerosing cholangitis and autoimmune pancreatitis. , 2018, , .		0
138	Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. <i>BMC Infectious Diseases</i> , 2018, 18, 461.	1.3	19
139	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 486.	2.2	91
140	Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1119-1135.	1.1	6
141	A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. <i>Frontiers in Immunology</i> , 2018, 9, 3175.	2.2	27
142	Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. <i>Journal of Clinical Investigation</i> , 2018, 128, 573-576.	3.9	4
143	Reply to: "Multiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic liver disease: A cautionary note on a promising technique". <i>Journal of Hepatology</i> , 2017, 66, 457-458.	1.8	2
144	Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1444-1452.e6.	2.4	116

#	ARTICLE	IF	CITATIONS
145	Phosphodiester content measured in human liver by in vivo ³¹ P MR spectroscopy at 7 tesla. <i>Magnetic Resonance in Medicine</i> , 2017, 78, 2095-2105.	1.9	25
146	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017, 49, 666-673.	9.4	129
147	No evidence to support a role for <i>Helicobacter pylori</i> infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. <i>Pancreatology</i> , 2017, 17, 395-402.	0.5	27
148	Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor- α neutralizing therapy in patients with inflammatory bowel disease. <i>Nature Medicine</i> , 2017, 23, 579-589.	15.2	571
149	Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101. <i>Hepatology</i> , 2017, 66, 57-68.	3.6	39
150	Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state. <i>Nucleic Acids Research</i> , 2017, 45, e148-e148.	6.5	77
151	Thoracic involvement in IgG4-related disease in a UK-based patient cohort. <i>Respiratory Medicine</i> , 2017, 132, 117-121.	1.3	29
152	Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. <i>Antiviral Research</i> , 2017, 146, 139-145.	1.9	14
153	IgG4-related sclerosing cholangitis. <i>Clinical Liver Disease</i> , 2017, 10, 9-16.	1.0	16
154	Immunology taught by rats. <i>Science</i> , 2017, 357, 129-130.	6.0	5
155	Interobserver Variability in Histologic Evaluation of Liver Fibrosis Using Categorical and Quantitative Scores. <i>American Journal of Clinical Pathology</i> , 2017, 147, 364-369.	0.4	49
156	Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. <i>Liver International</i> , 2017, 37, 1065-1073.	1.9	145
157	Hepatitis B vaccine shortage: another symptom of chronic neglect?. <i>BMJ: British Medical Journal</i> , 2017, 359, j4686.	2.4	3
158	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016, 4, 27.	2.1	35
159	Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR. <i>Emerging Infectious Diseases</i> , 2016, 22, 671-678.	2.0	46
160	Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. <i>Hepatology</i> , 2016, 64, 1377-1378.	3.6	12
161	Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2470-2484.	1.8	112
162	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. <i>Hepatology</i> , 2016, 63, 1455-1470.	3.6	43

#	ARTICLE	IF	CITATIONS
163	Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. <i>American Journal of Gastroenterology</i> , 2016, 111, 733-743.	0.2	167
164	Characterization of the Specificity, Functionality, and Durability of Host Tâ€Cell Responses Against the Fullâ€Length Hepatitis E Virus. <i>Hepatology</i> , 2016, 64, 1934-1950.	3.6	42
165	The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. <i>Gut</i> , 2016, 65, 112-123.	6.1	30
166	Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. <i>Journal of Hepatology</i> , 2016, 64, 308-315.	1.8	170
167	CD161intCD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. <i>Mucosal Immunology</i> , 2016, 9, 401-413.	2.7	121
168	Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus. <i>Wellcome Open Research</i> , 2016, 1, 9.	0.9	23
169	Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 944-947.	0.5	37
170	Screening and treatment for hepatitis C: a balanced perspective. <i>BMJ, The</i> , 2015, 350, h644-h644.	3.0	4
171	Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis. <i>Aids</i> , 2015, 29, 982-985.	1.0	2
172	A 63-year-old man with a recurrent right-sided pleural effusion: FigureÂ1. <i>Thorax</i> , 2015, 70, 504-507.	2.7	14
173	Crossâ€reactivity of hepatitis C virus specific vaccineâ€induced T cells at immunodominant epitopes. <i>European Journal of Immunology</i> , 2015, 45, 309-316.	1.6	34
174	An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes. <i>Virology</i> , 2015, 476, 355-363.	1.1	27
175	Therapeutic vaccines in HBV: lessons from HCV. <i>Medical Microbiology and Immunology</i> , 2015, 204, 79-86.	2.6	16
176	Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3155-3164.	1.8	28
177	Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. <i>Gastroenterology</i> , 2015, 149, 1462-1470.	0.6	214
178	Global distribution and prevalence of hepatitis C virus genotypes. <i>Hepatology</i> , 2015, 61, 77-87.	3.6	1,293
179	ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. <i>F1000Research</i> , 2015, 4, 1062.	0.8	66
180	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. <i>Science Translational Medicine</i> , 2014, 6, 261ra153.	5.8	297

#	ARTICLE	IF	CITATIONS
181	Hepatitis E Virus Infection, Papua New Guinea, Fiji, and Kiribati, 2003–2005. <i>Emerging Infectious Diseases</i> , 2014, 20, 1057-1058.	2.0	14
182	The emerging mysteries of IgG4-related disease. <i>Clinical Medicine</i> , 2014, 14, s56-s60.	0.8	3
183	Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. <i>Journal of Hepatology</i> , 2014, 60, 69-77.	1.8	367
184	Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. <i>Hepatology</i> , 2014, 59, 1954-1963.	3.6	158
185	Treatment of chronic viral hepatitis C in children and adolescents: UK experience. <i>Archives of Disease in Childhood</i> , 2014, 99, 505-510.	1.0	25
186	Type 1 Autoimmune Pancreatitis and IgG4-Related Sclerosing Cholangitis Is Associated With Extrapancreatic Organ Failure, Malignancy, and Mortality in a Prospective UK Cohort. <i>American Journal of Gastroenterology</i> , 2014, 109, 1675-1683.	0.2	210
187	Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 267-270.e6.	1.5	48
188	Effect of interferon- γ on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. <i>Psychological Medicine</i> , 2014, 44, 789-795.	2.7	23
189	Ever closer to a prophylactic vaccine for HCV. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1109-1124.	1.4	53
190	“Favourable” IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. <i>Journal of General Virology</i> , 2013, 94, 1259-1265.	1.3	19
191	Prevention of infection caused by immunosuppressive drugs in gastroenterology. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 167-185.	1.1	72
192	CD8 α Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2013, 4, 223.	2.2	26
193	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1741-1751.	1.4	6
194	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , 2013, 14, 1-71.	1.0	43
195	Emergence of a distinct HIV-specific IL-10-producing CD8 ⁺ T cell subset with immunomodulatory functions during chronic HIV infection. <i>European Journal of Immunology</i> , 2013, 43, 2875-2885.	1.6	4
196	Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6. <i>Journal of General Virology</i> , 2013, 94, 76-80.	1.3	21
197	A Modified RNA-Seq Approach for Whole Genome Sequencing of RNA Viruses from Faecal and Blood Samples. <i>PLoS ONE</i> , 2013, 8, e66129.	1.1	62
198	Infection Frequency of Hepatitis C Virus and IL28B Haplotypes in Papua New Guinea, Fiji, and Kiribati. <i>PLoS ONE</i> , 2013, 8, e66749.	1.1	8

#	ARTICLE	IF	CITATIONS
199	A rare cause of an ileocaecal mass and lymphadenopathy. <i>Gut</i> , 2012, 61, 819-820.	6.1	2
200	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. <i>Science Translational Medicine</i> , 2012, 4, 115ra2.	5.8	257
201	CD161+CD4+ T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN- γ . <i>Frontiers in Immunology</i> , 2012, 3, 346.	2.2	25
202	Human MAIT and CD8 α β cells develop from a pool of type-17 precommitted CD8+ T cells. <i>Blood</i> , 2012, 119, 422-433.	0.6	239
203	Discovery of Novel Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients: A Preliminary Study. <i>PLoS ONE</i> , 2012, 7, e39603.	1.1	40
204	Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. <i>Science Translational Medicine</i> , 2012, 4, 115ra1.	5.8	356
205	HCV genotype-3a T cell immunity: specificity, function and impact of therapy. <i>Gut</i> , 2012, 61, 1589-1599.	6.1	15
206	Vaccines in clinical trials: infectious disease. <i>Expert Review of Vaccines</i> , 2011, 10, 555-557.	2.0	0
207	New Approaches for Biomarker Discovery: The Search for Liver Fibrosis Markers in Hepatitis C Patients. <i>Journal of Proteome Research</i> , 2011, 10, 2643-2650.	1.8	18
208	Interferon lambdas: the next cytokine storm. <i>Gut</i> , 2011, 60, 1284-1293.	6.1	100
209	Vaccination for hepatitis C virus: closing in on an evasive target. <i>Expert Review of Vaccines</i> , 2011, 10, 659-672.	2.0	103
210	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011, 53, 1446-1454.	3.6	56
211	Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. <i>Hepatology</i> , 2010, 51, 54-62.	3.6	48
212	The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2010, 104, 475-483.	0.7	39
213	Failure to Detect Xenotropic Murine Leukemia Virus-Related Virus in Blood of Individuals at High Risk of Blood-Borne Viral Infections. <i>Journal of Infectious Diseases</i> , 2010, 202, 1482-1485.	1.9	40
214	Analysis of CD161 expression on human CD8 ⁺ T cells defines a distinct functional subset with tissue-homing properties. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3006-3011.	3.3	359
215	Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. <i>Journal of General Virology</i> , 2010, 91, 1396-1406.	1.3	28
216	What Are the Prospects for Controlling Hepatitis C?. <i>PLoS Medicine</i> , 2009, 6, e1000096.	3.9	9

#	ARTICLE	IF	CITATIONS
217	Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection. <i>Journal of Virology</i> , 2009, 83, 11456-11466.	1.5	27
218	Cellular Immune Responses during High-Dose Interferon- α Induction Therapy for Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 819-828.	1.9	47
219	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. <i>Hepatology</i> , 2009, 49, 1069-1082.	3.6	131
220	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009, 50, 1017-1029.	3.6	60
221	Genetic History of Hepatitis C Virus in East Asia. <i>Journal of Virology</i> , 2009, 83, 1071-1082.	1.5	190
222	Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2008, 15, 219-228.	1.0	31
223	Acute Hepatitis C: Clinical Aspects, Diagnosis, and Outcome of Acute HCV Infection. <i>Current Pharmaceutical Design</i> , 2008, 14, 1661-1665.	0.9	18
224	Immune Responses Against the Hepatitis C Virus and the Outcome of Therapy. , 2008, , 71-86.		0
225	The surveillance and diagnosis of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 491-496.	0.8	23
226	A Theoretical Framework for Quantitative Analysis of the Molecular Basis of Costimulation. <i>Journal of Immunology</i> , 2005, 175, 1575-1585.	0.4	49
227	T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. <i>Lancet, The</i> , 2005, 365, 327-329.	6.3	50
228	T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. <i>Lancet, The</i> , 2005, 365, 327-329.	6.3	13
229	Pervasive Influence of Hepatitis C Virus on the Phenotype of Antiviral CD8+ T Cells. <i>Journal of Immunology</i> , 2004, 172, 1744-1753.	0.4	98
230	Analysis of "driver" and "passenger" CD8 + T-cell responses against variable viruses. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2004, 271, S53-6.	1.2	17
231	Impact of Alpha Interferon and Ribavirin on the Function of Maturing Dendritic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3382-3389.	1.4	57
232	Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. <i>Journal of Viral Hepatitis</i> , 2004, 11, 324-331.	1.0	20
233	Ultra-sensitive class II tetramer analysis reveals previously undetectable populations of antiviral CD8+ T _H 1 cells. <i>European Journal of Immunology</i> , 2004, 34, 1570-1577.	1.6	57
234	High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. <i>Gastroenterology</i> , 2004, 127, 924-936.	0.6	276

#	ARTICLE	IF	CITATIONS
235	Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection. <i>Antiviral Therapy</i> , 2004, 9, 139-142.	0.6	13
236	Applications and Limitations of Blood Eosinophilia for the Diagnosis of Acute Cellular Rejection in Liver Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 432-438.	2.6	47
237	Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. <i>Immunology Letters</i> , 2003, 85, 165-171.	1.1	51
238	Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy, and success. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1855-1860.	3.3	61
239	T Cell Failure in Hepatitis C Virus Infection. <i>Viral Immunology</i> , 2002, 15, 285-293.	0.6	20
240	Immunity to hepatitis C virus: stunned but not defeated. <i>Microbes and Infection</i> , 2002, 4, 57-65.	1.0	30
241	Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2002, 109, 1406-1407.	1.1	77
242	The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. <i>Hepatology</i> , 2002, 36, 743-754.	3.6	132
243	Protecting travellers from hepatitis A. <i>BMJ: British Medical Journal</i> , 2001, 322, 1194-1195.	2.4	24
244	HCV genotypes' role in pathogenesis of disease and response to therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 229-240.	1.0	30
245	The science, economics, and effectiveness of combination therapy for hepatitis C. <i>Gut</i> , 2000, 47, 159-161.	6.1	4
246	PREDICTORS OF A FAVORABLE RESPONSE TO ALPHA INTERFERON THERAPY FOR HEPATITIS C. <i>Clinics in Liver Disease</i> , 1999, 3, 775-791.	1.0	12
247	Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. <i>Journal of Hepatology</i> , 1999, 31, 244-249.	1.8	15
248	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	20
249	Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
250	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
251	In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control. <i>Wellcome Open Research</i> , 0, 6, 47.	0.9	2
252	Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity " The OCTAVE Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	51

#	ARTICLE	IF	CITATIONS
253	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	15
254	Induction and maintenance of CX3CR1-intermediate peripheral memory CD8 T cells by persistent viruses and novel vaccines. SSRN Electronic Journal, 0, , .	0.4	0
255	Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Research, 0, 7, 51.	0.9	0
256	Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset. International Journal of Epidemiology, 0, , .	0.9	2